These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 37576702)

  • 21. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study.
    Dapoigny M; Piche T; Ducrotte P; Lunaud B; Cardot JM; Bernalier-Donadille A
    World J Gastroenterol; 2012 May; 18(17):2067-75. PubMed ID: 22563194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.
    Choi CH; Kwon JG; Kim SK; Myung SJ; Park KS; Sohn CI; Rhee PL; Lee KJ; Lee OY; Jung HK; Jee SR; Jeen YT; Choi MG; Choi SC; Huh KC; Park H
    Neurogastroenterol Motil; 2015 May; 27(5):705-16. PubMed ID: 25809913
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial.
    Chmielewska-Wilkoń D; Reggiardo G; Egan CG
    World J Gastroenterol; 2014 Sep; 20(34):12283-91. PubMed ID: 25232263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.
    Lorenzo-Zúñiga V; Llop E; Suárez C; Alvarez B; Abreu L; Espadaler J; Serra J
    World J Gastroenterol; 2014 Jul; 20(26):8709-16. PubMed ID: 25024629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of a Probiotic and an Antispasmodic Increases Quality of Life and Reduces Symptoms in Patients with Irritable Bowel Syndrome: A Pilot Study.
    Barraza-Ortiz DA; Pérez-López N; Medina-López VM; Minero-Alfaro JI; Zamarripa-Dorsey F; Fernández-Martínez NDC; Llorente-Ramón A; Ramos-Aguilar GA
    Dig Dis; 2021; 39(3):294-300. PubMed ID: 32810850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized double-blind placebo-controlled study to evaluate the effect of long-acting mesalamine on postinfectious irritable bowel syndrome with diarrhea.
    Tuteja AK; Leung DT; Fang JC; Talley NJ; Stoddard GJ
    Neurogastroenterol Motil; 2024 Oct; 36(10):e14889. PubMed ID: 39104061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chinese herbal formula Tongxie Yaofang for diarrhea-predominant irritable bowel syndrome: study protocol for a randomized, multiple-blind, placebo-controlled trial.
    Liang SB; Han M; Cheng HJ; Zhang QY; Zhang NW; Jia BY; Robinson N; Liu JP
    Trials; 2022 Mar; 23(1):226. PubMed ID: 35313933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of an amino acid beverage formulation in diarrhea-predominant irritable bowel syndrome: A pragmatic real-world study.
    Niles SE; Blazy P; Cheuvront SN; Kenefick RW; Vidyasagar S; Smith AB; Fawkes N; Denman W
    World J Gastrointest Pharmacol Ther; 2023 Dec; 14(5):39-49. PubMed ID: 38174291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): study protocol for a randomised controlled trial.
    Leighton MP; Lam C; Mehta S; Spiller RC
    Trials; 2013 Jan; 14():10. PubMed ID: 23302220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
    Weerts ZZRM; Masclee AAM; Witteman BJM; Clemens CHM; Winkens B; Brouwers JRBJ; Frijlink HW; Muris JWM; De Wit NJ; Essers BAB; Tack J; Snijkers JTW; Bours AMH; de Ruiter-van der Ploeg AS; Jonkers DMAE; Keszthelyi D
    Gastroenterology; 2020 Jan; 158(1):123-136. PubMed ID: 31470006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.
    Lembo A; Rao SSC; Heimanson Z; Pimentel M
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00144. PubMed ID: 32352714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS.
    Tack J; Schumacher K; Tonini G; Scartoni S; Capriati A; Maggi CA;
    Gut; 2017 Aug; 66(8):1403-1413. PubMed ID: 27196574
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Mourey F; Decherf A; Jeanne JF; Clément-Ziza M; Grisoni ML; Machuron F; Legrain-Raspaud S; Bourreille A; Desreumaux P
    World J Gastroenterol; 2022 Jun; 28(22):2509-2522. PubMed ID: 35979259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial.
    Shanshal SA; Alsaaty MH; Al-Qazaz H; Al-Zidan RN
    Ceska Slov Farm; 2024; 72(5):233-241. PubMed ID: 38195431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Two Lactobacilli strains as adjuvant therapy in the management of irritable bowel syndrome: a randomized control trial.
    Shanshal SA; Alsaaty MH; Al-Qazaz H; Al-Zidan RN
    Ceska Slov Farm; 2024; 73(1):233-241. PubMed ID: 38185646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
    Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.